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Presentation of Case
A 38-year-old man presented to a rural
hospital in Northwest Cameroon with a
one-month history of dyspnea that wors-
ened upon exertion. He reported occa-
sional cough, which was nonproductive.
Review of systems revealed a fall in weight
from 81 kg to 71 kg over the last year, but
no other problems were noted. The
patient initially sought care at a health
center in Douala (10 hours away by public
transport), where he was treated for
typhoid with no improvement.
On physical examination, temperature
was 37.8uC, blood pressure 110/
70 mmHg, pulse 88 beats per minute,
and respiratory rate 28 breaths per minute.
He was noncachectic without thrush or
lymphadenopathy. Lung auscultation re-
vealed no bronchial breath sounds or
wheezes, but decreased breath sounds and
dullness to percussion were noted at both
lung bases, and a chest radiograph showed
dense bibasilar opacities (Figure 1). Diag-
nostic thoracentesis confirmed the presence
of exudative pleural effusion; cytological
examination yielded 435 white blood cells/
mm
3 (84% lymphocytes, 10% neutrophils,
and 6% eosinophils), 240 red blood cells/
mm
3, and numerous motile microfilariae
(mff) throughout the specimen (see Video
S1). A smear was made of the pleural
aspirate and the filarial species identified as
Loa loa based on morphological features
(Figure 2). Other laboratory investigations
included hemoglobin of 9.3 mg/dl, white
blood cells 9,800/mm
3, a thick blood film
negative for malaria parasites, and a
positive HIV serology test. His CD4 count
was 954 cells/ml. Peripheral blood was not
examined for microfilariae.
After discussing these results with his
physician, the patient received a single
dose of ivermectin (150 mg/kg body
weight) and all other medications that
had been ordered by the admitting team—
including multiple broad-spectrum antibi-
otics, ventolin, and amodiaquine—were
stopped. A short course of prednisone was
initiated to reduce potential reaction to
parasite antigens. The next day, he left the
hospital in stable condition. Follow-up
examination three weeks later showed
normalization of his vital signs and total
resolution of the pleural effusions on
repeat radiography (Figure 1). The patient
was encouraged to participate in the
annual ivermectin campaigns common in
the area and to monitor his HIV infection
at his local medical center.
Case Discussion
Loiasis in sub-Saharan Africa
Loa loa is a filarial nematode transmitted
by Chrysops tabanid flies and is limited to
West and Central Africa. Most infected
people remain asymptomatic, but after a
latency period from 6 months to several
years, clinical symptoms may develop, most
often intermittent edematous lesions in the
extremities(Calabarswellings)orpassage of
the adult worm under the conjunctiva [1].
It is estimated that between 2 and 13
million people are infected with Loa loa, and
a recent survey in the Eastern Province of
Cameroon showed a microfilarial preva-
lence of over 20% in most villages and over
45% in several areas, with twice that level
of clinical manifestations [2]. There have
been rare reports of pulmonary involve-
ment manifested as eosinophilic infiltrates
[3,4] in Cameroon and one case of pleural
effusion that contained microfilariae of Loa
loa in a Ghanaian patient who had traveled
extensively in West Africa [5], but this case
is the first to describe pulmonary loiasis in a
known HIV-positive patient.
Treatment options
Effective treatment of loiasis includes
diethylcarbamazine (DEC) administered
over 2–4 weeks or a single dose of
ivermectin, but DEC is the only drug with
both micro- and macrofilaricidal activity
[1]. Definitive cure sometimes requires
repeated courses of DEC as some adult
worms survive the first treatment, and side
effects such as itching, rash, headache, and
fever are common. The microfilaricidal
effect of ivermectin lasts for over a year.
Both treatments can cause an often fatal
encephalopathy, especially in people with
high (30–50,000 mff/ml) microfilaremias,
characterized by aphasia, extrapyramidal
signs, incontinence, and retinal hemor-
rhage. In heavily infected patients, the mff
load can be reduced by a 3-week course of
albendazole, three sessions of apheresis, or
ivermectin prior to administering curative
DEC more safely [1].
When used for onchocerciasis control in
Cameroon, ivermectin caused functional
impairment in ,0.1% of cases and serious
neurological events in 1 per 10,000
patients, and it is estimated that microfil-
aremias above 8,000 mff/ml confer a risk
of postivermectin impairment [6]. This
patient was counseled about available
therapies as well as their risks, and he
chose ivermectin so as not to remain in the
hospital or on prolonged drugs. Loa loa
does not harbor symbiotic Wolbachia like
some nematodes, so doxycycline plays no
role in treatment of loiasis [7].
Helminth–HIV coinfection
The high prevalence of loiasis in
Cameroon mentioned above coexists with
an HIV prevalence estimated at 5.1% in
2007 [8]. The hypothesis that helminth
infections not only adversely affect the
progression of HIV disease but also
increase susceptibility to HIV infection in
the first place is garnering increasing
attention [9]. Normal immune responses
to HIV may be hampered by chronic
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type) and anergy. Indeed, peripheral blood
mononuclear cells from people with filarial
infections are more susceptible to HIV
infection in vitro [10]. Several prospective
cohort studies suggest helminth eradica-
tion in HIV-positive patients is associated
with reduced viral loads [11], and a recent
randomized control trial in Tanzania
showed significant beneficial effect on
HIV viral load after a course of DEC [12].
The Presenting Case
The case described here illustrates
several important points for clinicians in
the tropics. The initial management of the
patient was not as tailored as it could have
been, with intravenous antibiotics, anti-
malarials, and beta-agonists given all at
once in a kind of ‘‘shotgun’’ approach.
While empiric treatment for both malaria
and pneumonia is common in such
settings, admitting nurses and attending
doctors often rely upon algorithmic treat-
ment protocols not necessarily based on
clinical data. In this case, accurate initial
physical exam findings would have steered
the diagnosis in a more specific direction if
the pleural fluid had been promptly
analyzed.
In sub-Saharan Africa, most cases of
lymphocytic hemorrhagic exudative pleu-
ral effusion are tubercular, and, pending
pleural fluid analysis, the ward physician
was planning to initiate therapy for
extrapulmonary tuberculosis (TB). Differ-
ential diagnosis of such effusions includes
mainly malignancy—from primary bron-
chogenic to metastatic processes—and,
more rarely, fungal or resolving bacterial
infection. HIV-positive patients who wors-
en on TB treatment with ongoing hemor-
rhage often have pulmonary Kaposi’s
sarcoma. The unexpected finding of Loa
loa microfilariae in this effusion reminds us
that other explanations are possible, espe-
cially in HIV-positive patients who do not
improve with initial therapy or whose
CD4 count implies a relatively recent
seroconversion. Most often the causes of
Figure 1. Resolution of pleural effusions after treatment for loiasis. Chest radiographs showing bilateral basilar densities at the time of
admission (left) and complete resolution at 3-week follow-up after one dose of ivermectin (right).
doi:10.1371/journal.pntd.0000572.g001
Figure 2. Loa loa found in pleural aspirate of HIV-positive man in Cameroon. Microfilaria of Loa loa seen in Giemsa-stained preparation of
pleural fluid showing morphological characteristics including sheath and terminal nuclei (61,000). Note that Giemsa does not specifically stain the
sheath, but its outline is clearly visible in this preparation. Several lymphocytes can also be seen.
doi:10.1371/journal.pntd.0000572.g002
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above produce unilateral disease, and this
patient had bilateral findings, which may
be an indicator of atypical etiology.
Another possibility is that pleural microfi-
lariae are incidental findings in endemic
areas, but the patient’s recovery without
other treatment regimes supports a single
diagnosis, and antifilarial therapy led to
rapid clinical improvement in several prior
cases of pulmonary loiasis [3,4].
Pulmonary manifestations of Loa loa
infection include pulmonary infiltrates
and eosinophilic pleural effusion [1]. Once
the diagnosis was established, the physi-
cian suggested a course of DEC, but the
patient no longer wished to remain in the
hospital, despite being made aware of
potential severe adverse drug reactions
such as encephalitis. He agreed to stay for
24 hours after receiving the ivermectin for
monitoring as a compromise.
Although loiasis is the second or third
most common cause for consultation in
parts of Central Africa, it has received
relatively less attention than even other
filarial neglected tropical diseases [1]. The
case presented here serves as a reminder of
the high prevalence of Loa loa in Camer-
oon and that it can generate serious yet
atypical clinical manifestations. In this
HIV–Loa loa coinfected patient, it is
impossible to ascertain which infection
came first, but the high CD4 count and
early clinical stage suggests that the HIV
infection was relatively recent. Concerns
raised by the literature regarding immune
activation during helminth infection and
the resulting possibility that people infect-
ed with helminths are more susceptible to
HIV infection make it that much more
imperative for clinicians in the tropics to
be vigilant in their search for accurate
diagnoses, to be aware of locally prevalent
diseases and their treatment, and to say
‘‘yes’’ to the question ‘‘should we de-
worm?’’ [9] when these helminths are
encountered.
Supporting Information
Video S1 Live Loa loa in fresh pleural
fluid. Motile microfilaria seen in fresh
preparation of pleural aspirate seen under
low power prompted further investigation
of disease etiology.
Found at: doi:10.1371/journal.pntd.
0000572.s001 (5.59 MB AVI)
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Learning Points
N Not all lymphocytic pleural effusions in sub-Saharan Africa are due to
tuberculosis or malignancy.
N Eosinophilic effusions must be examined for microfilariae, and high CD4 counts
in HIV-positive patients with pleural effusion mandate broader differential
diagnosis and evaluation in areas where filariae are prevalent.
N There is increasing attention in the literature to the interaction between HIV
and helminths, and recent studies suggest helminth eradication may reduce
plasma viral load in coinfected patients.
N Caution must be exercised when using ivermectin in areas endemic for Loa loa,
as severe reactions including encephalopathy have been reported in patients
with very high microfilaria loads.
N Although more geographically restricted than other filarial diseases, loiasis
remains highly prevalent in parts of Central Africa and is the second or third
most common cause of medical consultation in some areas.
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